- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Tags
One-on-One's Investment biotech industry PUBLIC BIOTECH - Stock performance economic development drug development Health Care IPO 2012 BIO International Convention Industry Analysis BIOTECH FDA economy Events Partnering PUBLIC BIOTECH - Stats BIO International Convention Biotechnology Industry biotechnology patentAuthors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas, CFA
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Tracy Cooley
Latest From Biotech Now
New Patented Drugs Save Us All Money and Help Those in Dire Need
New patented drugs actually save the United States and its citizens lots of money. In fact, new drugs save 7 times more in non-drug spending than they cost. Those savings come as new drugs result in reduced hospital and nursing home admissions which far exceed the cost of using newer drugs. New patented prescription drugs can also reduce the need for expensive surgeries and hospital stays. This data clearly articulates that the cost of treating Read More >
Fox Trial Finder and You: Use It to Recruit for Your Trials or to Get Involved Yourself!
From The Michael J. Fox Foundation for Parkinson’s Research The Michael J. Fox Foundation has launched Fox Trial Finder, a new Web tool that uses state-of-the art technology to connect potential study volunteers with the coordinators of clinical studies that need someone with their specific medical history. The goal is to benefit both study sponsors and patients by getting people into clinical trials and studies faster — speeding the development of new treatments and ultimately a Read More >
2012 Orphan Disease Forum: Addressing Today’s Opportunities and Challenges
If all of the people with rare disease lived in one country, it would be the world’s third most populous country! Through dedicated companies such as the National Organization for Rare Disorders (NORD) and Centric Health Resources, the pressing issue of orphan diseases and its patients are being addressed. A rare disease is defined by any disease affecting fewer than 200,000 Americans. There are nearly 7,000 such diseases affecting over 350 million people worldwide. Furthermore, Read More >
2012 MassBioEd Innovative School of the Year – Norton High School
Massachusetts is home to the full ecosystem of life sciences—including our world class academic institutions and medical centers, a vibrant venture capital community, hundreds of biotech companies of all sizes, contract research and manufacturing organizations, and service organizations supporting the industry. It is no wonder then that eleven years ago MassBio established the Massachusetts Biotechnology Foundation to promote biotechnology education and workforce development programs. Each year, the Foundation awards the Innovative School of the Year Read More >
Indices, IPOs, and New Drug Approvals – Update April 3rd 2012
1. Stock Performance. The Nasdaq Biotech Index (NBI) continued to outperform in March, maintaining its Year-to-Date (YTD) lead of 18% vs. 12% for the S&P 500. Concentrated portfolios holding Amlyin, Regeneron, and Illumina came out even higher. For example, the Amex Biotech Index (BTK) is up 29% this year mainly because it held concentrated positions in these names. Amylin (ALMN) has doubled on the FDA approval for Bydureon and post-approval buy-out rumors. Illumina (ILMN) is up 72% Read More >
